AN2 Therapeutics, Inc. (ANTX) Financials
ANTX Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 81.7 million | 5.8 million |
| March 31, 2026 | 87.5 million | 5.7 million |
| Dec. 31, 2025 | 62.0 million | 8.9 million |
| Sept. 30, 2025 | 67.2 million | 6.9 million |
ANTX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -7.0 million | 972000 |
| March 31, 2026 | -12.1 million | 1.5 million |
| Dec. 31, 2025 | -5.2 million | 1.4 million |
| Sept. 30, 2025 | -6.4 million | 801000 |
ANTX Net Income
No data available :(
ANTX Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 78.4 million | - | - |
| March 31, 2026 | 85.3 million | - | - |
| Dec. 31, 2025 | 58.0 million | - | - |
| Sept. 30, 2025 | 61.9 million | - | - |
ANTX Shares Outstanding
ANTX Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | - | 6.0 million | 2.9 million | - |
| March 31, 2026 | - | 6.7 million | 3.8 million | - |
| Dec. 31, 2025 | - | 6.9 million | 2.4 million | - |
| Sept. 30, 2025 | - | 7.0 million | 3.0 million | - |
ANTX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | - | - |
| March 31, 2026 | - | - |
| Dec. 31, 2025 | - | - |
| Sept. 30, 2025 | - | - |
ANTX
Price: $5.99
52 week price:
Earnings Per Share: -1.05 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 47599
Market Capitalization: 225.7 million